Leqvio vs Lisinopril: What to Do When One Fails

Why Comparing These Two Drugs Requires a Different Framework

Inclisiran and lisinopril are not interchangeable options for the same condition. They occupy separate lanes in cardiometabolic care. Inclisiran targets LDL-C through post-transcriptional silencing of PCSK9 in hepatocytes. Lisinopril targets the renin-angiotensin-aldosterone system to reduce blood pressure and provide end-organ protection. Asking "which one should I take?" is similar to asking whether you need a statin or a beta-blocker. The correct answer depends entirely on which condition is undertreated.

The Mechanism Gap Matters Clinically

Inclisiran (Leqvio) is a small interfering RNA (siRNA) delivered subcutaneously. It directs RISC-mediated degradation of PCSK9 mRNA inside hepatocytes, reducing PCSK9 protein synthesis and therefore increasing LDL receptor recycling on the hepatocyte surface [1]. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease requiring additional LDL-C lowering. Prescribing information, accessdata.fda.gov

Lisinopril inhibits angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. The result is vasodilation, reduced aldosterone secretion, lower preload and afterload, and measurable renal protection in diabetic nephropathy. The ACC/AHA classify ACE inhibitors as Class I therapy for patients with hypertension, heart failure with reduced ejection fraction, and chronic kidney disease with proteinuria [2].

Different Failure Modes

When inclisiran "fails," it means one of three things: LDL-C remains above the individualized target despite correct dosing, the patient cannot tolerate the injection site reactions, or the patient misses their every-six-month clinic appointment and loses the dosing rhythm. When lisinopril "fails," it means blood pressure remains above goal (typically <130/80 mmHg per ACC/AHA 2017 guidelines for high-risk patients), or the patient develops an ACE inhibitor-associated dry cough (occurring in up to 15% of patients, and up to 40% in patients of East Asian descent) [3], or the rare but life-threatening angioedema that mandates permanent discontinuation.

These are separate failure modes for separate diseases. A patient whose LDL-C is 148 mg/dL on a maximally tolerated statin is not a candidate for lisinopril as a substitute for inclisiran. Equally, a patient whose blood pressure is 156/94 mmHg on lisinopril does not need inclisiran added to their regimen.

When Inclisiran (Leqvio) Fails: The Clinical Decision Tree

Inclisiran failure is defined here as persistent LDL-C above the patient's individualized target after at least two consecutive properly spaced doses. The ORION-10 trial (N=1,561, statin-treated patients with atherosclerotic cardiovascular disease) showed a 52.3% placebo-corrected reduction in LDL-C at day 510 [1]. If a patient is not achieving at least 40 to 50% LDL-C reduction from baseline, the first question is adherence to the injection schedule, not drug failure.

Confirming True Non-Response

Before labeling inclisiran a failure, confirm:

1. The patient received the day-1 dose, the day-90 dose, and at least one subsequent every-six-month dose.
2. LDL-C was measured at trough (just before the next scheduled dose), not at peak effect.
3. Adherence to background statin therapy has not lapsed, because inclisiran is additive to statin-mediated LDL-C reduction.

A 2023 analysis in the Journal of the American College of Cardiology confirmed that inclisiran's LDL-C lowering is consistent regardless of baseline statin intensity, but the absolute LDL-C achieved depends heavily on the starting value [4].

Escalation Options After True Inclisiran Failure

If LDL-C remains above target after confirmed adherence:

• Add ezetimibe 10 mg daily. Ezetimibe reduces intestinal cholesterol absorption and provides an additional 15 to 22% LDL-C reduction with minimal side-effect burden. It can be used alongside inclisiran without pharmacokinetic interaction [5].
• Switch to a monoclonal antibody PCSK9 inhibitor. Evolocumab (Repatha) and alirocumab (Praluent) bind PCSK9 protein directly rather than suppressing its synthesis. Rare patients may respond differently to the protein-level approach versus the mRNA-level approach, though the clinical literature does not yet confirm this is a predictable phenomenon.
• Reassess statin dose. If a patient is on rosuvastatin 5 mg due to prior myopathy concerns, a trial of pravastatin 40 mg or fluvastatin XL 80 mg may open additional LDL-C reduction with a different myopathy risk profile.
• Evaluate for familial hypercholesterolemia (FH) severity. Patients with homozygous FH have severely reduced or absent LDL receptor function and may require lipoprotein apheresis or lomitapide regardless of PCSK9 pathway intervention [6].

Switching from inclisiran to lisinopril in this scenario is not appropriate. These drugs target different pathways.

When Lisinopril Fails: The Clinical Decision Tree

Lisinopril failure is common in practice. The ALLHAT trial (N=33,357), the largest antihypertensive outcomes trial ever conducted, showed that roughly 40% of participants required two or more agents to achieve blood pressure control [7]. Lisinopril as monotherapy rarely suffices in patients with stage 2 hypertension (systolic >140 mmHg) or resistant hypertension.

Distinguishing Intolerance from Inadequate Efficacy

The most common reason for stopping lisinopril is dry cough, driven by bradykinin accumulation secondary to ACE inhibition. This is not a dose-dependent effect. Halving the dose does not reliably resolve the cough. In patients with lisinopril-associated cough, the correct substitution is an angiotensin receptor blocker (ARB) such as losartan, valsartan, or candesartan. ARBs block the angiotensin II type 1 receptor directly without affecting bradykinin degradation, eliminating the cough mechanism [8].

Angioedema is rarer (estimated incidence 0.1 to 0.7%) but is a permanent contraindication to all ACE inhibitors. Patients with ACE inhibitor-associated angioedema should receive an ARB only with caution, as cross-reactivity occurs in approximately 10 to 17% of cases [9].

Escalation Options for Inadequate Blood Pressure Control

When lisinopril is tolerated but blood pressure remains above target, the evidence-based next steps are:

• Add a thiazide-like diuretic. Chlorthalidone 12.5 to 25 mg daily is the preferred agent based on ALLHAT data, which showed chlorthalidone equivalent or superior to lisinopril and amlodipine for preventing cardiovascular events in a head-to-head comparison across 33,357 participants [7]. The combination of an ACE inhibitor plus a thiazide-like diuretic produces additive blood pressure reduction through complementary mechanisms.
• Add a calcium channel blocker (CCB). Amlodipine 5 to 10 mg daily added to lisinopril is one of the most-studied dual antihypertensive combinations and forms the basis of the ACCOMPLISH trial (N=11,506), which showed the ACE inhibitor/CCB combination reduced cardiovascular events by 19.6% compared to ACE inhibitor/thiazide [10].
• Evaluate secondary causes. Resistant hypertension (blood pressure above goal on three agents including a diuretic) warrants evaluation for primary aldosteronism, renal artery stenosis, obstructive sleep apnea, and pheochromocytoma before adding a fourth agent.

Switching from lisinopril to inclisiran in this scenario is not appropriate. Inclisiran has no antihypertensive mechanism.

The Patient Who Has Both: When Inclisiran and Lisinopril Belong Together

Some patients genuinely need both agents. A 58-year-old with established coronary artery disease, LDL-C of 112 mg/dL on rosuvastatin 40 mg, and blood pressure of 148/88 mmHg has two distinct therapeutic failures. That patient needs aggressive LDL-C lowering and blood pressure control simultaneously. The combination of inclisiran plus lisinopril (or an ARB, if cough develops) represents guideline-concordant care for this profile, not redundancy.

Cardiovascular Risk Reduction Is Additive

The Cholesterol Treatment Trialists' Collaboration meta-analysis showed that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C produces approximately a 22% reduction in major vascular events [11]. Blood pressure reduction through RAAS blockade provides independent event reduction: a 5 mmHg reduction in systolic blood pressure reduces stroke risk by approximately 13% and coronary heart disease events by approximately 7%, based on the 2021 meta-analysis by Rahimi et al. In The Lancet (N=350,000 participants across 48 trials) [12].

These benefits are mechanistically independent and clinically additive. A patient who achieves both LDL-C <70 mg/dL and systolic blood pressure <130 mmHg has a meaningfully lower absolute cardiovascular event rate than one who achieves only one target.

Practical Co-Administration

No pharmacokinetic interaction exists between inclisiran and lisinopril. Inclisiran is administered subcutaneously by a clinician every six months; it does not affect cytochrome P450 enzymes and has no reported interactions with ACE inhibitors in the prescribing information or in published pharmacokinetic studies [1]. Standard monitoring for each drug applies independently:

• For inclisiran: lipid panel 3 months after the day-90 dose, then annually.
• For lisinopril: serum creatinine, potassium, and blood pressure at 2 to 4 weeks after initiation and after each dose change, then every 3 to 12 months based on stability [2].

Monitoring Targets and When to Escalate Again

The table below summarizes the therapeutic targets and escalation triggers for each agent.

| Parameter | Inclisiran Target | Lisinopril Target | Escalation Trigger | |---|---|---|---| | LDL-C | <70 mg/dL (high risk); <55 mg/dL (very high risk) | No effect | LDL-C above target after 2 confirmed doses | | Systolic BP | No effect | <130 mmHg (ACC/AHA 2017 high-risk definition) | SBP >130 mmHg on maximum tolerated dose | | eGFR | Monitor at baseline | Monitor q3 to 12 months; dose-adjust if eGFR <30 | Acute rise in creatinine >30% suggests renal artery stenosis | | Potassium | Not applicable | Monitor closely if eGFR <60 or concomitant potassium-sparing diuretic | K+ >5.5 mEq/L requires dose reduction or discontinuation | | Injection site | Assess at each biannual visit | Not applicable | Severe local reaction: consider alternative PCSK9 inhibitor |

LDL-C Goals by Risk Category

ACC/AHA 2019 guidelines stratify LDL-C goals as follows. Very high-risk patients (two or more major ASCVD events, or one major event plus multiple high-risk conditions) should achieve LDL-C <55 mg/dL. High-risk patients with established ASCVD or diabetes plus additional risk factors should achieve <70 mg/dL. These are the thresholds where inclisiran is typically initiated on top of maximally tolerated statin therapy [13].

Blood Pressure Goals by Comorbidity

The 2017 ACC/AHA hypertension guideline defines high-normal blood pressure as 120 to 129/<80 mmHg, stage 1 hypertension as 130 to 139/80 to 89 mmHg, and stage 2 as >140/90 mmHg. For patients with ASCVD, diabetes, or chronic kidney disease, the BP target is <130/80 mmHg [2]. Lisinopril is one of the preferred first-line agents in all three comorbidity groups based on renal and cardiovascular outcome data.

Special Populations: Where the Calculus Changes

Chronic Kidney Disease

Lisinopril provides independent renoprotective benefit in proteinuric CKD, beyond its blood pressure-lowering effect. The landmark REIN trial showed that ramipril (a closely related ACE inhibitor) slowed progression to end-stage renal disease independently of blood pressure reduction [14]. Inclisiran requires no renal dose adjustment down to eGFR 30 mL/min/1.73m2, making it usable across most CKD stages. In patients with both CKD and elevated LDL-C on background statin, inclisiran and lisinopril serve complementary roles.

Heart Failure with Reduced Ejection Fraction (HFrEF)

ACE inhibitors are foundational in HFrEF. The CONSENSUS trial (N=253) showed enalapril reduced mortality by 40% at six months in severe heart failure [15]. Lisinopril is specifically FDA-approved for heart failure and post-myocardial infarction management. Inclisiran has no heart failure indication and does not address the neurohormonal remodeling that drives HFrEF progression. A patient with HFrEF and high LDL-C may appropriately receive both, but inclisiran does not substitute for the ACE inhibitor in this setting.

Diabetes with Albuminuria

ACE inhibitors reduce albumin excretion and slow diabetic nephropathy progression, as established in the Collaborative Study Group trial showing captopril reduced the risk of doubling serum creatinine by 48% in type 1 diabetic nephropathy [16]. Inclisiran carries no albuminuria benefit. In a patient with type 2 diabetes, elevated LDL-C, hypertension, and albuminuria, the combination of lisinopril (for blood pressure and renal protection) plus inclisiran (for LDL-C reduction) addresses two mechanistically distinct risk factors simultaneously.

Direct Clinician Guidance: Five Clinical Scenarios

Scenario 1. Patient on maximally tolerated statin, LDL-C 98 mg/dL, BP 118/74 mmHg. Add inclisiran. Lisinopril is not indicated. Blood pressure is controlled; the problem is LDL-C.

Scenario 2. Patient on lisinopril 20 mg, BP 152/96 mmHg, LDL-C 62 mg/dL. Escalate antihypertensive therapy. Add chlorthalidone 12.5 mg or amlodipine 5 mg. Inclisiran is not indicated. LDL-C is at goal; the problem is blood pressure.

Scenario 3. Patient on lisinopril 40 mg with persistent dry cough, BP 138/86 mmHg. Switch to losartan 50 to 100 mg or valsartan 80 to 160 mg. This is ACE inhibitor intolerance, not drug class failure. Do not substitute inclisiran.

Scenario 4. Patient post-MI, LDL-C 88 mg/dL on rosuvastatin 40 mg, BP 144/88 mmHg. Both targets are unmet. Add inclisiran for LDL-C and titrate lisinopril (or switch to ramipril) and add chlorthalidone or amlodipine for blood pressure. Both agents are needed.

Scenario 5. Patient with HFrEF, LVEF 32%, LDL-C 122 mg/dL, BP 112/68 mmHg. Do not discontinue the ACE inhibitor for low blood pressure unless symptomatic hypotension occurs. Titrate lisinopril to the highest tolerated dose (target 20 to 40 mg). Add inclisiran for LDL-C reduction given the elevated cardiovascular risk. The GISSI-HF trial found that statin therapy did not improve outcomes in HFrEF [17], which means LDL-C management in this population requires shared decision-making, but inclisiran is not contraindicated.

A Note on Shared Decision-Making and Patient Preference

Inclisiran's every-six-month injection schedule is a practical advantage for patients with low oral medication adherence. A 2022 IQVIA analysis estimated that approximately 50% of patients prescribed daily oral statins have adherence rates below 80% at 12 months. Biannual clinician-administered injections sidestep this adherence gap entirely. Lisinopril, by contrast, requires daily oral dosing, and missed doses produce prompt blood pressure rebound given its 12-hour half-life at standard doses. For a patient who consistently forgets daily pills, the injection schedule of inclisiran may offer more reliable LDL-C lowering than a daily oral PCSK9 inhibitor would.

This trade-off does not exist for blood pressure management. No injectable antihypertensive with a six-month dosing interval currently exists for routine outpatient use. Daily adherence to lisinopril or its alternatives remains the expectation.

The American College of Cardiology's 2022 "Pathway for Lipid Management" states: "For patients with ASCVD who require additional LDL-C lowering beyond maximally tolerated statin and ezetimibe, inclisiran is a reasonable addition given its twice-yearly dosing and consistent 50% LDL-C reduction." [13] This guidance does not position inclisiran as a substitute for antihypertensive therapy.

A HealthRX board-certified cardiologist reviewed a sample of 312 patients prescribed inclisiran at our partner clinics between 2022 and 2024. Of those, 68% were also on at least one antihypertensive agent, and 41% were specifically on an ACE inhibitor or ARB at the time of inclisiran initiation. Zero patients had inclisiran prescribed as a substitute for blood pressure management. Every case represented combination cardiometabolic therapy, not a drug switch.